X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Elevar gain rights to commercialize and develop Hengrui’s anti-PD-1 antibody SHR-1210 (camrelizumab), in combination with rivoceranib (aka apatinib) for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.
Lead Product(s): Camrelizumab,Rivoceranib
Therapeutic Area: Oncology Product Name: SHR-1210
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Elevar Therapeutics
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 17, 2023
Details:
Apatinib (rivoceranib), a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
Apatinib (rivoceranib), a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of VEGFR-2, a primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancer.
Lead Product(s): Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tanner Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Apatinib (rivoceranib) is a tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 in combination with AiRuiKa (camrelizumab) a humanized mAb targeting the PD-1 receptor, is being investigated for unresectable hepatocellular carcinoma.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jiangsu Hengrui Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Rivoceranib (apatinib) is the first small-molecule tyrosine kinase inhibitor approved in gastric cancer in China (November 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.
Lead Product(s): Camrelizumab,Rivoceranib
Therapeutic Area: Oncology Product Name: SHR-1210
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jiangsu Hengrui Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Apatinib (rivoceranib), is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer in China, highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Lead Product(s): Rivoceranib,Camrelizumab
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Results of Study RM-202 demonstrated clinical effectiveness of Apatinib for treatment of patients, indicated by substantially reduced tumor progression during 6 months after rivoceranib treatment compared to that during 6 months prior to rivoceranib treatment.
Lead Product(s): Rivoceranib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Rivoceranib (Apatinib) demonstrated meaningful results, with an overall response rate (ORR) of 15.1%, median duration of response (DoR) of 14.9 months, median progression-free survival (PFS) of 9 months and disease control for ≥3 months in over 60% of patients.
Lead Product(s): Rivoceranib
Therapeutic Area: Oncology Product Name: Apatinib
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
